The New England journal of medicine
-
Editorial Comment
Treatment by CRISPR-Cas9 Gene Editing - A Proof of Principle.
-
Randomized Controlled Trial Multicenter Study
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown. ⋯ In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.).